IL15 and neoplasm: Likewise, the result of tumor weight (Fig 7D and 7E) was correlated with the result of tumor volume, where final tumor weights of the mice treated with Pembrolizumab-IL-15Rα-IL-15 were 94.14% decreased (0.10 ± 0.09 g) and the mice treated with Keytruda were 83.43% decreased (0.29 ± 0.19 g) from the control group (1.77 ± 0.13 g).